MorphoSys AGNASDAQ:MOR
- LAST PRICE18.1300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 18.1300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MOR |
|---|---|---|
| 09:32 ET | 4557 | 18.02 |
| 09:34 ET | 3348 | 18.04 |
| 09:36 ET | 518 | 18.04 |
| 09:38 ET | 518 | 18.04 |
| 09:39 ET | 1534 | 18.04 |
| 09:41 ET | 1536 | 18.03 |
| 09:43 ET | 618 | 18.05 |
| 09:45 ET | 2009 | 18.06 |
| 09:48 ET | 474 | 18.05 |
| 09:50 ET | 2670 | 18.04 |
| 09:52 ET | 1150 | 18.04 |
| 09:54 ET | 516 | 18.04 |
| 09:56 ET | 227 | 18.04 |
| 09:59 ET | 1890 | 18.06 |
| 10:01 ET | 495 | 18.05 |
| 10:03 ET | 2498 | 18.05 |
| 10:06 ET | 100 | 18.06 |
| 10:10 ET | 1800 | 18.0401 |
| 10:12 ET | 1000 | 18.06 |
| 10:14 ET | 5177 | 18.07 |
| 10:15 ET | 1500 | 18.07 |
| 10:19 ET | 100 | 18.09 |
| 10:30 ET | 599 | 18.09 |
| 10:32 ET | 1294 | 18.09 |
| 10:33 ET | 382 | 18.08 |
| 10:42 ET | 3392 | 18.08 |
| 10:44 ET | 500 | 18.1 |
| 10:50 ET | 100 | 18.1 |
| 11:00 ET | 240 | 18.1 |
| 11:02 ET | 2900 | 18.11 |
| 11:04 ET | 303 | 18.11 |
| 11:06 ET | 2419 | 18.1 |
| 11:08 ET | 200 | 18.09 |
| 11:27 ET | 5110 | 18.12 |
| 11:29 ET | 2522 | 18.12 |
| 11:42 ET | 600 | 18.1272 |
| 11:44 ET | 485 | 18.13 |
| 11:45 ET | 100 | 18.14 |
| 11:49 ET | 3100 | 18.12 |
| 11:54 ET | 200 | 18.134 |
| 11:56 ET | 835 | 18.14 |
| 12:00 ET | 100 | 18.145 |
| 12:03 ET | 200 | 18.14 |
| 12:05 ET | 500 | 18.14 |
| 12:07 ET | 100 | 18.12 |
| 12:36 ET | 500 | 18.13 |
| 12:52 ET | 100 | 18.13 |
| 12:59 ET | 100 | 18.1399 |
| 01:01 ET | 213 | 18.14 |
| 01:03 ET | 282 | 18.13 |
| 01:06 ET | 200 | 18.14 |
| 01:08 ET | 657 | 18.14 |
| 01:10 ET | 462 | 18.14 |
| 01:15 ET | 317 | 18.14 |
| 01:17 ET | 569 | 18.135 |
| 01:19 ET | 100 | 18.13 |
| 01:24 ET | 400 | 18.13 |
| 01:28 ET | 100 | 18.13 |
| 01:30 ET | 100 | 18.14 |
| 01:35 ET | 200 | 18.14 |
| 01:48 ET | 1110 | 18.135 |
| 01:53 ET | 100 | 18.14 |
| 02:02 ET | 111 | 18.135 |
| 02:06 ET | 129 | 18.135 |
| 02:13 ET | 119 | 18.135 |
| 02:20 ET | 100 | 18.13 |
| 02:27 ET | 110 | 18.135 |
| 02:36 ET | 217 | 18.13 |
| 02:47 ET | 124 | 18.135 |
| 03:03 ET | 157 | 18.135 |
| 03:05 ET | 200 | 18.135 |
| 03:23 ET | 360 | 18.13 |
| 03:25 ET | 1604 | 18.125 |
| 03:27 ET | 300 | 18.11 |
| 03:30 ET | 516 | 18.12 |
| 03:34 ET | 100 | 18.11 |
| 03:41 ET | 108 | 18.115 |
| 03:52 ET | 400 | 18.12 |
| 03:54 ET | 9942 | 18.12 |
| 03:56 ET | 2419 | 18.13 |
| 03:57 ET | 200 | 18.12 |
| 03:59 ET | 11552 | 18.13 |
Apr 24, 2024
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting, from 11:02AM ET on Wednesday Apr 24, 2024 by Dow Jones
11:02AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 11, 2024
DJ Trending: Novartis Begins Tender Offer for MorphoSys Shares, from 3:36PM ET on Thursday Apr 11, 2024 by Dow Jones
3:36PM ET on Thursday Apr 11, 2024 by Dow JonesMorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis, from 9:01AM ET on Thursday Apr 11, 2024 by Dow Jones
9:01AM ET on Thursday Apr 11, 2024 by Dow JonesMorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis, from 8:39AM ET on Thursday Apr 11, 2024 by Dow Jones
8:39AM ET on Thursday Apr 11, 2024 by Dow JonesPress Release: MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis, from 8:39AM ET on Thursday Apr 11, 2024 by Dow Jones
8:39AM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MorphoSys AG | 2.7B | -12.1x | --- |
Arrowhead Pharmaceuticals Inc | 2.9B | -7.9x | --- |
Axsome Therapeutics Inc | 3.4B | -13.8x | --- |
Genmab A/S | 18.7B | 28.9x | +22.71% |
Amicus Therapeutics Inc | 3.1B | -19.8x | --- |
TG Therapeutics Inc | 2.2B | 985.1x | --- |
Company Information
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Contact Information
- Headquarters
- Semmelweisstr. 7PLANEGG, Germany 82152
- Phone
- ---
- Fax
- 898-992-7222
Executives
- Independent Chairman of the Supervisory Board
- Marc Cluzel
- Chairman of the Management Board, Chief Executive Officer
- Jean-Paul Kress
- Independent Deputy Chairman Member of the Supervisory Board
- George Golumbeski
- Chief Financial Officer, Member of the Executive Committee
- Lucinda Crabtree
- Senior Vice President, Head of Corporate Affairs, Member of the Executive Committee
- Thomas Biegi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $255.6M |
Shares Outstanding | 150.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.15 |
EPS | $-1.50 |
Book Value | $0.35 |
P/E Ratio | -12.1x |
Price/Sales (TTM) | 10.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -106.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
